In conclusion, our results reveal that low concentrations of metformin, of the same order as those measured in the plasma and tissues of individuals who have received a recommended therapeutic dose of metformin, selectively inhibits the proliferation of CD133+ pancreatic cancer cells and has an anticancer action both in vitro and in vivo. Here, PROM1 is linked to familial pancreatic carcinoma.